NEW YORK, Dec. 20, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into NovoCure Limited (NVCR) (“NovoCure”). If you are a NovoCure shareholder, you are encouraged to contact Scott+Scott at (800) 404-7770, email [email protected] or go to: http://www.scott-scott.com/cases/investigations/securities-fraud-litigation-3079-novocure-limited.html.
NovoCure develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (“TTFields”). NovoCure markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.
On July 28, 2016, NovoCure announced that its new Optune prescriptions fell to 657 in 2Q from 755 in 1Q. Asaf Danziger, Chief Executive Officer of Novocure stated that “[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
On this news, NovoCure’s stock fell from a July 27, 2016 price of $11.44 to a July 28, 2016 price of $8.09, a one-day decline of over 29%.
If you are a NovoCure shareholder and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Michael Burnett at (800) 404-7770, or at [email protected].
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott have significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.
CONTACT: Michael Burnett Scott+Scott, Attorneys at Law, LLP (800) 404-7770 [email protected]


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



